<DOC>
	<DOCNO>NCT02969265</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TCV-116CCB ( candesartan cilexetil amlodipine besylate fixed-dose combination ) Chinese participant mild moderate hypertension reach target blood pressure follow 4 week treatment amlodipine monotherapy .</brief_summary>
	<brief_title>An Efficacy Safety Study Evaluating Fixed-Dose Combination Candesartan Plus Amlodipine Participants With Mild/Moderate Essential Hypertension</brief_title>
	<detailed_description>The drug test study call TCV-116CCB ( candesartan cilexetil amlodipine besylate fixed-dose combination ) . This study look blood pressure Chinese participant grade 1 2 essential hypertension . The study enroll approximately 370 patient . Prior start study treatment , participant undergo run-in period 2 week follow single-blind treatment period 4 week . Upon completion single-blind treatment period , participant randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Amlodipine 5 mg - TCV-116CCB ( Candesartan 8 mg Plus Amlodipine 5 mg ) All participant ask take one tablet/capsule time day throughout study 8 week . This multicenter trial conduct China . The overall time participate study 19 week . Participants make multiple visit clinic , contact telephone plus final visit 14 day receive last dose drug follow-up assessment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Has grade 1 2 essential hypertension adequately control , define mean , trough , sit , clinic systolic blood pressure ( SBP ) : 1 . ≥155 &lt; 180 mm Hg participant receive antihypertensive medication 14 day prior Visit 1 . 2 . ≥145 ≤170 mm Hg participant take 1 antihypertensive medication Visit 1 . 3 . ≥140 &lt; 160 mm Hg participant take 2 antihypertensive medication Visit 1 . 2 . Is willing discontinue current antihypertensive medication . Entering amlodipine 5 mg monotherapy : 3 . Must clinic SBP measurement 155 179 mm Hg inclusive ( determine mean 3 sit , trough , measurement Day 28 , use arm throughout study ) qualify entry 4 week singleblind amlodipine 5 mg monotherapy treatment period . At doubleblind randomization : 4 . Has achieve target blood pressure ( define clinic SBP ≥140 mm Hg determine mean 3 sit , trough , measurement ) follow 4 week singleblind treatment amlodipine 5 mg monotherapy Day 1 prior randomization doubleblind treatment . 1 . Has clinic SBP ≥180 mm Hg DBP ≥110 mm Hg . 2 . The participant 's 3 SBP measurement differ 15 mm Hg ( confirmed second set three measurement ) . 3 . Has randomized/enrolled amlodipine candesartan candesartan/amlodipine Fixed dose combination study . 4 . Has secondary hypertension etiology ( e.g. , renovascular disease document cause hypertension , pheochromocytoma , Cushing 's syndrome ) . 5 . Has history myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention , hypertensive encephalopathy , cerebrovascular accident , persistent permanent atrial fibrillation transient ischemic attack . 6 . Has clinically significant cardiac conduction defect ( e.g. , thirddegree atrioventricular block , sick sinus syndrome ) . 7 . Has hemodynamically significant leave ventricular outflow obstruction due aortic valvular disease hypertrophic cardiomyopathy . 8 . Has history cancer remission least 5 year prior first dose singleblind amlodipine monotherapy study drug . ( This criterion apply participant basal cell Stage 1 squamous cell carcinoma skin ) . 9 . Has poorlycontrolled type 1 2 diabetes mellitus ( hemoglobin A1c [ HbA1c ] &gt; 8.0 % ) Screening . 10 . Has severe renal dysfunction disease ( base estimate Glomerular filtration rate [ GFR ] &lt; 30 mL/min/1.73m^2 ) Screening . 11 . Has hypokalemia hyperkalemia ( define serum potassium outside normal reference range ) Screening . 12 . Has alanine aminotransferase aspartate aminotransferase level &gt; 2.5 time upper limit normal , active liver disease , jaundice Screening . 13 . Works night ( third ) shift ( defined 10 PM [ 2200 ] 6 AM [ 0600 ] ) ( Only participant ambulatory blood pressure monitor [ ABPM ] ) . 14 . Has upper arm circumference &lt; 24 cm &gt; 42 cm ( Only participant ABPM ) . Entering amlodipine 5 mg monotherapy period : 15 . Has clinic SBP ≥180 mm Hg DBP ≥110 mm Hg . 16 . Is noncompliant ( &lt; 80 % &gt; 120 % ) study medication placebo runin period . Postsingleblind amlodipine 5 mg treatment period : 17 . Achieves target blood pressure ( define clinic SBP &lt; 140 mm Hg determine mean 3 sit , trough measurement ) follow 4 week singleblind treatment amlodipine 5 mg monotherapy Day 1 , prior randomization doubleblind treatment . 18 . Has clinic SBP ≥180 mm Hg or/and DBP ≥110 mm Hg . 19 . Is noncompliant ( &lt; 80 % &gt; 120 % ) study medication amlodipine 5 mg singleblind treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>